NVS vs ORKA
NVS: Global pharmaceutical and biotechnology company pioneering disease-modifying treatments across oncology, immunology, neuroscience, and rare genetic diseases. ORKA: Clinical-stage biopharmaceutical company developing novel monoclonal antibodies with extended half-life for inflammatory and immunology indications, led by IL-23p19 and IL-17A/F targeted programs for psoriasis and related conditions.
Side-by-side fundamentals
| Metric | NVS | ORKA | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $153.08 | $92.53 | |
| Market cap as of 2026-07-23 | $229.2B | $5.6B | |
| P/E as of 2026-07-23 | 22.11 | n/a | |
| PEG as of 2026-07-23 | 3.66 | n/a | |
| Net margin as of 2026-07-23 | +22.5% | -26.3% | NVS higher |
| Gross margin as of 2026-07-23 | +75.0% | n/a | |
| Operating margin as of 2026-07-23 | +29.9% | -40.3% | NVS higher |
| ROE as of 2026-07-23 | +29.9% | -26.0% | NVS higher |
| ROA as of 2026-07-23 | +11.1% | -25.0% | NVS higher |
| Debt / equity as of 2026-07-23 | 1.18 | 0.00 | ORKA lower |
| Revenue growth (YoY) as of 2026-07-23 | +3.3% | n/a | |
| Dividend yield as of 2026-07-23 | +3.0% | n/a | |
| Beta as of 2026-07-23 | 1.17 | -0.38 | |
| 1-year return as of 2026-07-22 close | +35.8% | +558.1% | ORKA higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.